Sickle cell anaemia: Progress in pathogenesis and treatment

Drugs

Volumn 62, Issue 8, 2002, Pages 1143-1172

  Ballas, Samir K ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIBIOTIC AGENT; CAPSAICIN; CHOLINE MAGNESIUM TRISALICYLATE; CORTICOSTEROID; DEOXYHEMOGLOBIN; DIFLUNISAL; EMLA; FENOPROFEN; FLURBIPROFEN; HEMOGLOBIN S; HYDROXYUREA; IBUPROFEN; INDOMETACIN; KETOPROFEN; LIDOCAINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PARACETAMOL; PENICILLIN DERIVATIVE; PRILOCAINE; PROPIONIC ACID DERIVATIVE; SALICYLIC ACID DERIVATIVE; SALSALATE; SULINDAC; TOLMETIN; TRAMADOL; UNINDEXED DRUG;

ACUTE CHEST SYNDROME; ARTIFICIAL VENTILATION; BLOOD GROUP KELL SYSTEM; BLOOD GROUP RH; BLOOD TRANSFUSION; BLOOD VESSEL OCCLUSION; BONE MARROW TRANSPLANTATION; DRUG INDUCED DISEASE; EDUCATION; EMPLOYMENT; EXCHANGE BLOOD TRANSFUSION; FAMILY; GENE THERAPY; HUMAN; HUMAN RELATION; INFLAMMATION; IRON OVERLOAD; MULTIPLE ORGAN FAILURE; PAIN; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PATIENT EDUCATION; PHENOTYPE; RELIGION; REPERFUSION INJURY; REVIEW; SICKLE CELL ANEMIA; SOCIAL INTERACTION; TRANSGENIC MOUSE; UMBILICAL CORD BLOOD;

MUS MUSCULUS; PROTEA;

EID: 0036271425     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262080-00003     Document Type: Review

References (185)

1. Sickle cell anemia, a molecular disease
2. Hydroxyurea: Effects on hemoglobin F production in patients with sickle cell anemia
3. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
4. Hydroxyurea and sickle cell anemia: Clinical utility of a myelosuppressive 'switching' agent: The Multi-center Study of Hydroxyurea in Sickle Cell Anemia
5. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia
6. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin
7. Gene mutations in human haemoglobin. The chemical difference between normal and sickle cell haemoglobin
8. Large cerebral vessel disease in sickle cell anemia
9. The natural history of stroke in sickle cell disease
10. Sickle cell anemia and major organ failure
11. Beyond hemoglobin polymerization: The red blood cell membrane and sickle disease pathophysiology
12. Vascular occlusion in sickle cell disease: Current concepts and unanswered questions
13. Regulation of erythrocytes cation and water content in sickle cell anemia
14. Cation transport and volume regulation in sickle red blood cells
15. Prevention of red cell dehydration: A possible new treatment for sickle cell disease
16. A mathematical model of the volume, pH1 and ion content regulation in reticulocytes: Application to the pathophysiology of sickle cell dehydration
17. Regulation of cation content and cell volume in hemoglobin erythrocytes from patients with homozygous hemoglobin C disease
18. Inhibition of K transport by divalent cations in sickle erythrocytes
19. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease
20. Compartmentation of sickle cell calcium in endocytic inside-out vesicles
21. Compartmentation of Ca2+ in sickle cells
22. Endocytosis in sickle erythrocytes: A mechanism for elevated intracellular Ca2+ levels
23. Erythrocyte adherence to endothelium in sickle cell anemia: A possible determinant of disease severity
24. Abnormal adherence of sickle cell erythrocytes to cultured vascular endothelium: Possible mechanism for microvascular occlusion in sickle cell disease
25. Adhesion of normal and sickle erythrocytes to endothelial monolayer cultures
26. Rheological studies of erythrocyte-endothelial cell interactions in sickle cell disease
27. Sickle cell vaso-occlusion
28. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse
29. Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: Pathophysiological implications
30. Adherence of sickle erythrocytes to vascular endothelial cells; requirement for both cell membrane changes and plasma factors
31. Sickle reticulocytes adhere to VCAM-1
32. a4b1-integrin expression on sickle reticulocytes: Vascular cell adhesion molecular-1-dependent binding to endothelium
33. Platelet hyperactivity in sickle cell disease: A consequence of hyposplenism
34. Significance of plasma beta-thromboglobulin values in patients with sickle cell disease
35. Platelet activation during steady state sickle cell disease
36. Thrombospondin. Phenomenology to function
37. Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells
38. Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: A potential role for platelet activation in sickle cell vaso-occlusion
39. P-selectin mediates the adhesion of sickle erythrocytes to the endothelium
40. Occlusion of large cerebral vessels in sickle cell anemia
41. Sickle cell anemia and central nervous system infarction: A neuropathological study
42. Hypofibronectinaemia and severity of sickle cell anaemia
43. Hypoxia/moxygenation causes inflammatory response in transgenic sickle mice but not in normal mice
44. Sickle cell anemia as an inflammatory disease
45. Monoclonal antibodies to αvβ3 (7E3 and LM609) inhibit sickle red blood cell endothelium interaction induced by platelet activating factor
46. Blockade of adhesion of sickle cells to endothelium by monoclonal antibodies
47. Thalassemia in blacks: Genetic and clinical aspects and interactions with the sickle hemoglobin gene
48. The Senegal DNA haplotype is associated with the amelioration of anemia in African-American sickle cell anemia patients
49. Sickle cell anemia bs-gene-cluster haplotypes as prognostic indicators of vital organ failure
50. Rheologic predictors of the severity of the painful sickle cell crisis
51. The painful crisis of homozygous sickle cell disease: A study of risk factors
52. Pain in sickle cell disease: Rates and risk factors
53. The prevalence of avascular necrosis in sickle cell anemia: Correlation with athalassemia
54. Sickle cell disease as a cause of osteonecrosis of the femoral head
55. Leg ulcers in patients with sickle cell disease
56. Alpha thalassemia and stroke risk in sickle cell anemia
57. Is Hb A2 elevated in adults with sickle-α-thalassemia (Bs/Bs;-α/-α)?
58. Molecular characteristics of pediatric patients with sickle cell anemia and stroke
59. Evidence for the multicentric origin of the hemoglobin S gene in Africa
60. Gender and haplotype effects upon hematological manifestations of adult sickle cell anemia
61. Fetal hemoglobin in sickle cell anemia: Relationship to erythrocyte adhesion markers and adhesion
62. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells: A review
63. Short survival of phosphatidylserine exposing red blood cells in murine sickle cell anemia
64. Fetal hemoglobin in sickle cell disease: Relationship to erythrocyte phosphatidylserine exposure and coagulation activation
65. Evidence for HLA-related susceptibility for stroke in children with sickle cell disease
66. Frequency of the 677C◇T mutation of the methylenetetrahydrofolate reductase gene among Kuwati sickle cell patients
67. Palliative medicine: An emerging field of specialization
68. Peripheral neuropathy in adults with sickle cell disease
69. Sickle cell anemia day hospital: An approach for the management of uncomplicated painful crises
70. Treatment of pain in adults with sickle cell disease
71. Impact of non-narcotic oral analgesics on pain management
72. Efficacy and safety of acetaminophen, aspirin and caffeine in alleviating migraine headache pain
73. Non-narcotic analgesics
74. Non-steroidal anti-inflammatory drugs
75. COX-2 inhibitors
76. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis
77. Immune thrombocytopenia resulting from sensitivity to metabolites of naproxen and acetaminophen
78. Are selective COX-2 inhibitors nephrotoxic?
79. Effects of celecoxib and naproxen on renal function in the elderly
80. Enhancement of pain control with kerorolac tromethamine in patients with sickle cell vaso-occlusion crisis
81. Tramadol: An alternative analgesic to traditional opioids and NSAIDS
82. Opioids
83. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate tolerance/dependence liability
84. Systemic analgesics
85. Meperidine biotransformation and central nervous system toxicity in animals and humans
86. Opioids and akathisia
87. Cancer pain relief and palliative care
88. Narcotic analgesic use among adult patients with sickle cell anemia
89. Playing with Pain Killers
90. Sickle cell disease: Clinical management
91. Consensus document for transfusion-related iron overload
92. Indications for red cell transfusion in sickle cell disease
93. Transfusion therapy for cerebrovascular abnormalities in sickle cell disease
94. Effect of transfusion therapy on arteriorgraphic abnormalities and on recurrence of stroke in sickle cell disease
95. A modified transfusion program for prevention of stroke in sickle cell disease
96. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: A multicenter transfusion trial
97. Current therapy for chronic hepatitis-C
98. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis-C virus infection: Role of membrane oxidative damage
99. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease
100. Prophylaxis with oral penicillin in children with sickle cell anemia
101. Policy Statement: Recommendations for the prevention of pneumococcal infections, including the case of pneumoccal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine and antibiotics prophylaxis
102. Management of community-acquired pneumonia in the era of pneumococcal resistance
103. Management of cerebral vasculopathy in children with sickle cell anaemia
104. The use of transcranial ultrasonography to predict stroke in sickle cell disease
105. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography
106. Hydroxyurea as an alternative to blood transfusion for the prevention of recurrent stroke in children with sickle cell disease
107. Homocysteine in sickle cell disease: Relationship to stroke
108. Acute chest syndrome in adults with sickle cell anemia
109. Acute chest syndrome in sickle cell disease. Clinical presentation and course. Cooperative study of sickle cell disease
110. 'Blister cells': Association with pregnancy, sickle cell disease and pulmonary infarction
111. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease
112. Causes of death in sickle cell disease in Jamaica
113. Comprehensive care in sickle cell disease: Its impact on morbidity and mortality
114. Acute chest syndrome in sickle cell disease: Pathophysiology and management
115. Causes and outcomes of the acute chest syndrome in sickle cell disease
116. Acute chest syndrome in sickle cell anemia
117. The acute chest syndrome in sickle cell disease: Incidence and risk factors. The cooperative study of sickle cell disease
118. Mortality in sickle cell disease: Life expectancy and risk factors for early death
119. Acute chest syndrome of sickle cell disease: A new light on an old problem
120. Sickle cell acute chest syndrome: Pathogenesis and rationale for treatment
121. Microvascular hemodynamics in the sickle red blood cell perfused isolated rat lung
122. Pulmonary fat embolism: A distinct cause of severe acute chest syndrome in sickle cell anemia
123. Outpatient penile aspiration and epinephrine irrigation for young patients with sickle cell anemia
124. Phospholipase A2 levels in acute chest syndrome of sickle cell disease
125. Rib infarcts and acute chest syndrome
126. Elevated serum and bronchoalveolar lavage fluid levels of IL-8 and G-CSF associated with the acute chest syndrome in patients with sickle cell disease
127. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease
128. Sickling crisis, fat embolism and coma after steroids
129. Inhaled nitric oxide in sickle cell disease with acute chest syndrome
130. RheothRx (Poloxamer 188) injection for the acute painful episode of sickle cell disease
131. Increased whole blood viscosity during coronary artery bypass surgery. Studies to evaluate the effects of soluble fibrin and poloxamer 188
132. Renal abnormalities in sickle cell disease
133. Hyperkalemic hyperchloremic metabolic acidosis in sickle cell hemoglobinopathies
134. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme
135. Hematuria and sickle cell disease: A report of 12 cases and review of the literature
136. Clinical hematological and biochemical features of Hr SC disease
137. Priapism: Sickle cell disease
138. Modified method of exchange transfusion in sickle cell disease
139. The variable expression of sickle cell disease is genetically determined
140. The spectrum of painful episodes in adult sickle cell disease
141. A possible role for hydroxyurea therapy
142. Leg ulcers in patients tested with hydroxyurea for myeloproliferative disorders: What is the trigger?
143. Five years of experience with hydroxyurea in children and young adults with sickle cell disease
144. Clinical evaluation of a semi-permeable polymeric membrane dressing for the treatment of chronic diabetic foot ulcers
145. Core decompression in avascular necrosis of the hip in sickle cell disease
146. Long term results of total hip arthroplasty for osteonecrosis of the femoral head: A comparison with osteoarthritis
147. Osteonecrosis of the hip in sickle cell diseases
148. Total replacement of the hip for avascular necrosis in sickle cell disease
149. Cholecystectomy in sickle cell anemia patients: Perioperative outcome of 364 cases from the National Preoperative Transfusion study
150. Cholecystectomy in adult patients with sickle cell disease
151. Influence of bilirubin uridine diphosphate-glucoronosyltransferase 1A promotor polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia
152. Genetic determinants of jaundice and gallstones in haemoglobin E b-thalassemia
153. Exchange transfusion in sickle cell intrahepatic cholestasis
154. Bone marrow transplantation for sickle cell disease
155. Successful related cord blood transplantation for hemoglobinopathies
156. Unrelated placental umbilical cord blood cell (UCBC) transplantation in children with high-risk sickle cell disease (SCD)
157. Successful cord blood transplantation for sickle cell anemia from a sibling who is human leukocyte antigen-identical: Implications for comprehensive care
158. Correction of sickle cell disease in transgenic mouse models by gene therapy
159. Hydroxyurea exposure alters mouse testicular kinetics and sperm chromatin structure
160. Comparison of teratogenic effects of aspirin and hydroxyurea in the Fischer 344 and Wistar strains
161. Severe developmental malformations: Malformations induced by urethane and hydroxyurea in the hamster
162. Acute leukemia (AL), hydroxyurea (HO) and polycythemia vera (PV): An analysis of risk and the Polycythemia Vera Study Group
163. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease
164. A short-term trial of burtyate to stimulate fetal-globin-gene expression in the b-globin disorders
165. Fetal hemoglobin induction with butyric acid: Efficacy and toxicity
166. Isobutyramide therapy in patients with sickle cell anemia
167. Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate
168. Increased fetal hemoglobin production in patients receiving valproic acid for epilepsy
169. Stimulation of hemoglobin synthesis by erythropoietin in baboons
170. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease
171. Granulocytosis causing sickle cell crisis
172. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration
173. Granulocyte colony-stimulating factor-inducted sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell b+ thalassemia
174. Inhibition of Ca2+-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives
175. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease
176. Pulmonary hypertension in sickle cell disease and treatment with L-Carritine
177. Arginine therapy: A new treatment for pulmonary hypertension in sickle cell disease
178. Zileuton: A potential new treatment approach for acute chest syndrome
179. Sickle cell anemia: A potential nutritional approach for a molecular disease
180. Green tea extract and aged garlic extract inhibit potassium chloride co-transport in sickle cells in vitro, but Vitamin-C and Vitamin-E do not
181. Hydration of sickle erythrocytes using a herbal extract (Pfaffia paniculata) in-vitro